Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03406247
Title Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris

oropharynx cancer

laryngeal squamous cell carcinoma

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma


Ipilimumab + Nivolumab


Age Groups: adult | senior
Covered Countries FRA

No variant requirements are available.